Get the full picture
Sign in to uncover key details.
SP
Director, Clinical Operations
JK
Director, Neuroscience
Get the full picture
Sign in to uncover key details.
Kallyope
Manufacturing · New York, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
430 E 29th St Fl 10, New York, New York,...Website
www.kallyope.comRevenue
$15.1 MillionIndustry
About Kallyope
TriGemX Bio is a biotechnology company focused on developing innovative medicines for the treatment of migraine, leveraging insights into neural signaling pathways. Founded by leading neuroscientists, the company is advancing its late-stage pipeline with a first-in-class medication, Elismetrep, currently in Phase 3 trials. The team combines agile innovation with a real-world focus to create significant value for patients. Based in New York City, TriGemX Bio emphasizes collaboration and a culture of thinkers and doers to tackle major health challenges.Explore more
Kallyope Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Compare Similar Companies to Kallyope
Compare insights from companies similar to Kallyope, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Kallyope Tech Stack
A closer look at the technologies used by Kallyope
See more technologies
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Kallyope
Sign Up For FreeTo access detailed company insights
TriGemX Bio is a biotechnology company focused on developing innovative medicines for the treatment of migraine, leveraging insights into neural signaling pathways. Founded by leading neuroscientists, the company is advancing its late-stage pipeline with a first-in-class medication, Elismetrep, currently in Phase 3 trials. The team combines agile i... Read More
